Phase III Plans in the Works
Cytokinetics’ Phase II HF Data: Traders Skeptical, Amgen Not
By Randy Osborne
Staff Writer
Staff Writer
Tuesday, September 3, 2013
Cytokinetics Inc. and licensor Amgen Inc. will wait until a Phase II study in chronic heart failure with orally given omecamtiv mecarbil generates data to decide the fate of the compound, which fizzled in a Phase II trial testing the intravenous form of the cardiac myosin activator against acute heart failure.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.